Pathways of Neurodevelopmental Disorders
Organizer(s): Randi J. Hagerman, Mustafa Sahin and Paul J. HagermanDate: March 16 - 20, 2015
Location: Granlibakken Tahoe, Tahoe City, CA, USA
Advances in genetics and animal models for many neurodevelopmental disorders have led to the development of targeted treatments that can reverse neurobiological abnormalities in the animal models. Human studies have begun to show significant benefit from targeted treatments for several neurodevelopmental disorders including fragile X syndrome, tuberous sclerosis, Angelman Syndrome, Down Syndrome, Rett Syndrome and neurofibromatosis, with the potential for many more. There are remarkable commonalities in the dysfunction of key pathways and the molecular mechanisms involved in synaptic plasticity across neurodevelopmental disorders. This Keystone Symposia meeting covers advances in targeted treatments for several neurodevelopmental disorders with an emphasis on common pathways across disorders and treatments that may help more than one disorder. The conference also addresses the gap between how environmental factors including seizures and toxins can impact genetically vulnerable populations, such as those with neurodevelopmental problems, and the molecular mechanisms including mitochondrial dysfunction, oxidative stress, miRNA dysregulation and neuroinflammation that are involved. The goal of this conference is to stimulate development of new treatments and biomarkers to assess treatments in neurodevelopmental disorders and to promote early intervention with prophylactic and targeted treatments. By pulling together basic science and translational clinical trials, and mixing clinicians with molecular biologists and neurobiologists, the meeting should foster new ideas for treatment that will be beneficial across the spectrum of neurodevelopmental disorders.
Scholarship Deadline: November 18 2014
Discounted Abstract Deadline: November 18 2014
Abstract Deadline: December 16 2014
Discounted Registration Deadline: January 15 2015
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Novartis Institutes for BioMedical Research
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Neurological Disorders and Stroke (NINDS)
Grant No. 1R13NS090680-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.